Early Phase 1
N=58
Lavender vs Zolpidem Sleep Quality During Diagnostic PSG
Sleep
Bottom Line
View on ClinicalTrials.gov: NCT04102345 ↗Enrolled (actual)
58
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcome: Primary: Sleep Efficiency — 77.6; 76.8 percentage of time in bed sleeping
Study Design & Population
- Study type
- Interventional
- Phase
- Early Phase 1
- Interventions
- Lavender Aromatherapy (Other); Zolpidem (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- HealthPartners Institute
- Primary completion
- Nov 2020
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Sleep Efficiency |
77.6; 76.8 | — |
| SECONDARY Number of Participants With A Successful Polysomnogram (PSG) |
24; 28 | — |
| SECONDARY Wake After Sleep Onset (WASO) |
52.3; 53.7 | — |
Summary
In this pragmatic, clinical study the investigators propose that lavender aromatherapy is comparable to Zolpidem (Ambien) in improving the quality of diagnostic sleep studies.
Eligibility Criteria
Inclusion Criteria
- Age >=18 years
- In-center diagnostic or split night sleep study (PSG)
Exclusion Criteria
- No exclusion criteria
Data sourced from ClinicalTrials.gov (NCT04102345). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.